Q32 Bio reels in $60m Series B

Cambridge, Massachusetts-based Q32 Bio, a developer of biologic therapeutics to restore healthy immune regulation, has closed $60 million in Series B financing.

Cambridge, Massachusetts-based Q32 Bio, a developer of biologic therapeutics to restore healthy immune regulation, has closed $60 million in Series B financing. OrbiMed Advisors and Acorn Bioventures led the round.

Source: Press Release